Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%
HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$5.21B
EPS-4.2200
P/E Ratio-19.95
Earnings Date08/10/2026

apge

Total Assets

Last Annual Value

937.13M

3-Year CAGR

83%

5-Year CAGR

44%

10-Year CAGR

20%

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Competitors Analysis of Total Assets

APGE · NASDAQ
CompanyTotal Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
937.13M
32.7%N/AN/A 
1.73B
-2.1%9.1%N/A
1.53B
0.9%0.1%11.0%
791.59M
58.4%68.3%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
466.56M
34.6%40.3%54.4%
806.88M
29.9%54.2%N/A
563.83M
46.1%73.8%58.7%
Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Fair Value Envelope

APGE · NASDAQ

Our analysis suggests that APGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.19, this represents a potential HIDDEN relative to our calculated worth for Apogee Therapeutics, Inc..

Intrinsic Value
Current Price: $84.19